| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a5b94ab4f8a1f31a93553a5db231cd |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate |
2006-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29f13d87686428414e533cd62680ed12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_395ce1d00a68f7f16243f8f8d12c9f2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a77a03f6a8b3b3fe215fb22fe186d36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f632d1e9f24dfbf0e5f969e81bfe8778
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dab677be9b06ee507443ef2ce4c9a4f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e259200aae6a9b69f61804dbb505a3e |
| publicationDate |
2008-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20080065622-A |
| titleOfInvention |
Bioactive Substrate Carrier for Stabilized Blood Delivery, Complexes Comprising the Same, and Method for Blood Delivery of Bioactive Substrate Using the Same |
| abstract |
In the present invention, a disulfanyl group designed to modify modified bioactive matrix compounds is conjugated with plasma proteins, especially free thiol group (Cys 34 ) of serum albumin, to form a 'new and stable disulfide (SS) covalent bond'. It provides a method of enhancing the half-life and stability of the body.n n n The present invention provides an effective analysis method that can be qualitatively and quantified in vitro by conjugation with designed disulfanyl group plasma proteins.n n n The present invention provides a method for preparing the bioactive substrate compound by appropriate molecular design so that the disulfide covalent bond between the bioactive substrate compound and the plasma protein in the blood can be effectively conjugation.n n n The present invention specifically provides pharmacological therapeutic effects and methods of treatment of modified designed bioactive matrix compounds. |
| priorityDate |
2005-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |